Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. - Wikidata - wikimedia - TriplyDB

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

http://www.wikidata.org/entity/Q34659408

about

Proliferative and non-proliferative lesions of the rat and mouse soft tissue, skeletal muscle and mesothelium.Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists Development of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities.Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.Mechanistic Pathways in Amide Activation: Flexible Synthesis of Oxazoles and Imidazoles.Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat.PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.Early toxicology signal generation in the mouse.Direct N-alkylation of unprotected amino acids with alcohols.

P2860

Q33880079-E87AB9DB-DCE2-495A-94E4-3CE70770FA9F Q36073447-BAD6D66B-D64D-4A59-B52C-E837E0165A1A Q37077098-BD36B057-E746-4CB5-90DE-F820E032AD81 Q37137719-B42232F5-CEA6-4FFD-AB7F-353B48FC4930 Q38061184-B088231C-23BC-49C4-B134-EE0DB67A3D8E Q39771912-A408CBAB-9A38-4174-8908-2412F37E7069 Q41110549-F58D72FC-6506-4993-9705-1A1F7F5EFBDF Q42728391-8C63CD31-BFEA-4156-855B-694ECF976548 Q43222810-09F63C95-5650-459D-B4AE-E175D3A0E0FF Q43287595-F0F578AB-2011-4B97-A5F9-ADACC2BCD344 Q46170974-4C4EB73C-109E-4838-AADB-9FF6EA4350C0 Q47094747-A4BDA113-0513-43E9-9A6D-1ECB010BB197

P2860

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

http://www.wikidata.org/entity/Q34659408

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@ast

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@en

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@nl

type

label

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@ast

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@en

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@nl

prefLabel

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@ast

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@en

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@nl

P1433

Q34659408-B866C4F5-E319-4667-9DEA-7ADA3E76B802

P1476

Q34659408-AF502875-29C2-4B52-86CF-A1BBBB8600E2

P2093

Q34659408-971B2DD8-6BD9-41E0-8467-C267187DCB83

Q34659408-A4AA70B8-DBE8-4080-9DFF-85809A9E28F6

Q34659408-AE33B9F9-28F3-4A4B-A633-59712FCDB7EF

Q34659408-BD447B47-1EE7-432A-8BDB-13D39DB4833F

P2860

Q34659408-027C27EF-9DAC-4B35-A0C8-06201EAA181A

Q34659408-0EDCE633-9222-4C79-A2D7-D25FA40152C9

Q34659408-0FC45827-D665-4DAF-897A-C76E207E7C68

Q34659408-1149CC1E-2F73-4320-8A87-7D37B06C7D7A

Q34659408-1B5EE642-E6B0-438F-B3AC-827C0630C91E

Q34659408-29FBB0C7-BA2F-4A86-A5D0-4C3AA7C66989

Q34659408-2F89CB9C-5346-442E-898D-E504D51445B9

Q34659408-3EAC5492-310E-45BE-8AE8-CB5D192826C4

Q34659408-47E3CEEF-6E65-4FD7-AC1F-8F2CAB71664C

Q34659408-483C495C-B4DF-411B-B639-BD29A979BFA2

P304

Q34659408-3E933EE0-C618-4B9A-945A-112D538718D8

P31

Q34659408-8F634F25-C667-4086-8738-970F1595A80D

P356

Q34659408-A346555D-D46F-463C-953F-BC8ED5CF2CB6

P433

Q34659408-49F07FB4-96B5-4D80-9268-BF9A63095360

P478

Q34659408-4652C31D-2F32-4D56-8048-5DB607ACDD87

P577

Q34659408-D1418EEB-9667-4D27-A255-1E9F57A2CD0D

P5875

Q34659408-ADB274ED-0478-4248-B33B-BDCC154B7237

P698

Q34659408-31194530-2E66-435C-B277-668A681E9D00

P356

P1433

Toxicological Sciences

P1476

Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.

@en

P2093

Beth E Schilling

http://www.w3.org/2001/XMLSchema#string

Crystal R Waites

http://www.w3.org/2001/XMLSchema#string

Mark A Dominick

http://www.w3.org/2001/XMLSchema#string

Thomas P Sanderson

http://www.w3.org/2001/XMLSchema#string

P2860

The mechanisms of action of PPARs

Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat

Roles of PPARs in health and disease.

Thiazolidinediones.

Metabolic and additional vascular effects of thiazolidinediones.

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

PPARalpha agonist-induced rodent tumors: modes of action and human relevance.

PPAR trilogy from metabolism to cancer.

Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.

The many faces of PPARgamma.

P304

248-258

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/TOXSCI/KFM193

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6163039

http://www.w3.org/2001/XMLSchema#string

P698

17675651

http://www.w3.org/2001/XMLSchema#string